HLB Innovation's U.S. subsidiary, Verismo Therapeutics, has secured an additional next-generation target for solid tumors, advancing its CAR-T therapy pipeline. The company plans to accelerate the development of next-generation cell therapies that improve treatment durability in solid tumors based on its platform.
Verismo announced on July 21 that it has initiated preclinical development of a new target binder that recognizes the cancer cell surface antigen 'Claudin 6 (CLDN6)' through a research collaboration with the University of Pennsylvania (UPenn).
The CLDN6 binder was discovered by a research team led by Dr. Donald Siegel at UPenn's Perelman School of Medicine, marking the second proprietary binder secured by Verismo through its collaboration with UPenn. Previously, the company obtained the DS191 binder, which is applied to its hematologic cancer CAR-T candidate 'SynKIR-310'.
CLDN6 is an antigen that is minimally expressed in normal adult tissues but is found in various solid tumors, making it a promising target for next-generation immuno-oncology therapies. Recent studies have confirmed its antitumor activity across various therapeutic approaches, including CAR-T, antibody-drug conjugates (ADCs), and bispecific antibodies, highlighting its clinical potential.
Verismo aims to combine its proprietary CLDN6 binder with its multi-chain KIR-CAR platform to enhance the durability of effects, which has been a limitation of existing CLDN6-targeted therapies, and to induce a more stable anti-tumor immune response in solid tumors.
Brian Kim, CEO of Verismo, stated, "Applying the KIR-CAR platform to the promising solid tumor target CLDN6 is a strategic choice to overcome the limitations of existing treatments. We will expand the application of the platform to various solid tumors."
Meanwhile, Verismo is conducting Phase 1 clinical trials for its solid tumor CAR-T 'SynKIR-110' and hematologic cancer CAR-T 'SynKIR-310' at major cancer centers in the U.S. Notably, SynKIR-110 garnered attention for confirming safety and tumor reduction signals in early dose cohorts, as reported in interim data presented at the American Association for Cancer Research (AACR) in April.
Verismo announced on July 21 that it has initiated preclinical development of a new target binder that recognizes the cancer cell surface antigen 'Claudin 6 (CLDN6)' through a research collaboration with the University of Pennsylvania (UPenn).
The CLDN6 binder was discovered by a research team led by Dr. Donald Siegel at UPenn's Perelman School of Medicine, marking the second proprietary binder secured by Verismo through its collaboration with UPenn. Previously, the company obtained the DS191 binder, which is applied to its hematologic cancer CAR-T candidate 'SynKIR-310'.
CLDN6 is an antigen that is minimally expressed in normal adult tissues but is found in various solid tumors, making it a promising target for next-generation immuno-oncology therapies. Recent studies have confirmed its antitumor activity across various therapeutic approaches, including CAR-T, antibody-drug conjugates (ADCs), and bispecific antibodies, highlighting its clinical potential.
Verismo aims to combine its proprietary CLDN6 binder with its multi-chain KIR-CAR platform to enhance the durability of effects, which has been a limitation of existing CLDN6-targeted therapies, and to induce a more stable anti-tumor immune response in solid tumors.
Brian Kim, CEO of Verismo, stated, "Applying the KIR-CAR platform to the promising solid tumor target CLDN6 is a strategic choice to overcome the limitations of existing treatments. We will expand the application of the platform to various solid tumors."
Meanwhile, Verismo is conducting Phase 1 clinical trials for its solid tumor CAR-T 'SynKIR-110' and hematologic cancer CAR-T 'SynKIR-310' at major cancer centers in the U.S. Notably, SynKIR-110 garnered attention for confirming safety and tumor reduction signals in early dose cohorts, as reported in interim data presented at the American Association for Cancer Research (AACR) in April.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.